SCHEDULE: ADAR1 Capital Management Discloses Pliant Therapeutics Stake

ADAR1 Capital Management, LLC and Daniel Schneeberger have jointly filed a Schedule 13G, reporting beneficial ownership of 8.9% of Pliant Therapeutics, Inc. common stock as of June 30, 2026.

Summary

• ADAR1 Capital Management, LLC and Daniel Schneeberger have filed a Schedule 13G, indicating their beneficial ownership of Pliant Therapeutics, Inc. common stock.
• As of June 30, 2026, the reporting persons collectively beneficially owned 5,509,724 shares of common stock.
• This ownership represents 8.9% of the class of securities outstanding.
• The filing is made in accordance with Rule 13d-1(b) and is based on information from Pliant Therapeutics' Form 10-Q for the period ended June 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative disclosure of beneficial ownership rather than a strategic or financial update.

Positives

• Clear disclosure of significant beneficial ownership by ADAR1 Capital Management and Daniel Schneeberger.
• The filing confirms a substantial stake (8.9%) in Pliant Therapeutics, Inc.

Negatives

• No new financial performance data or strategic initiatives are disclosed in this filing.
• The filing is purely an ownership disclosure, offering no insight into the company's operational performance or future prospects.

Risks

• The filing does not contain specific risk factors related to Pliant Therapeutics' operations, but the concentration of ownership could imply potential influence on corporate decisions.
• Future changes in beneficial ownership by ADAR1 Capital Management could impact Pliant Therapeutics' stock price and corporate control.

Future Outlook

This filing does not contain any forward-looking statements or guidance from Pliant Therapeutics, Inc. It is solely an ownership disclosure.

Management Comments

• ADAR1 Capital Management, LLC and Daniel Schneeberger certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant shareholders to disclose their holdings. This filing indicates ADAR1 Capital Management's substantial investment in the biotechnology sector, specifically in Pliant Therapeutics.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by ADAR1 Capital Management may influence investor perception and trading activity.
• Management of Pliant Therapeutics: The substantial ownership by an investment firm could lead to increased engagement or influence on corporate strategy.

Next Steps

• ADAR1 Capital Management, LLC and Daniel Schneeberger will continue to report any changes in their beneficial ownership of Pliant Therapeutics, Inc. common stock as required by SEC regulations.

Key Dates

Keywords

Pliant Therapeutics, Schedule 13G, ADAR1 Capital Management, Beneficial Ownership, Common Stock, Investment Management, SEC Filing